MSD MULTI-SPOT · V-PLEX

Preclinical Safety · DILI · AKI · Cardiotoxicity

MSD Preclinical Toxicology Panel — Liver, Kidney & Cardiac Safety Biomarkers

Integrated preclinical toxicology biomarker panels covering liver, kidney, cardiac, and skeletal muscle injury — all on the same MSD platform. 25 µL EDTA plasma per panel enables serial multi-organ safety assessment from a single animal across repeat-dose toxicology studies.

Liver: Arginase-1 (liver-specific) + GST-α (earliest release) — both PSTC/FDA-recognized, measured simultaneously on MULTI-SPOT. Kidney: KIM-1, NGAL, Clusterin, Osteopontin, Cystatin C — covering tubular injury (KIM-1, NGAL), glomerular injury (Cystatin C), and functional impairment. Cardiac: cTnI, cTnT, FABP3 — the same cardiac troponins used in clinical translation, measured via ECL with fg/mL sensitivity in rat and mouse. Muscle: sTnI, Myl3, FABP3 — skeletal-specific injury markers to distinguish muscle from cardiac injury. All panels run on one MSD instrument from 25 µL each — a 100 µL serial plasma sample supports liver, kidney, cardiac, and muscle assessment at every timepoint.

Inquire About Toxicology Panels View Panel Configurations

Multi-Organ Safety — Why Single-Organ Biomarkers Are No Longer Sufficient

Traditional preclinical toxicology relies on histopathology — the gold standard for organ injury confirmation — but histopathology requires terminal sacrifice, providing a single endpoint snapshot rather than temporal injury kinetics. Clinical chemistry markers (ALT, AST, BUN, creatinine) are non-terminal but lack organ specificity and sensitivity: ALT/AST cannot distinguish liver from muscle injury; BUN and creatinine rise only after >50% nephron loss. The shift toward translational safety biomarkers — driven by the PSTC (Predictive Safety Testing Consortium) and regulatory qualifiers from the FDA and EMA — has produced organ-specific protein biomarkers with superior sensitivity, specificity, and temporal resolution: Arginase-1 and GST-α for liver, KIM-1 and NGAL for kidney, cardiac troponins I/T and FABP3 for heart, sTnI and Myl3 for skeletal muscle. Electrochemiluminescence (ECL) enables all these organ-specific biomarkers to be measured on a single platform from microliter plasma volumes — transforming preclinical toxicology from terminal histopathology to serial, within-animal, multi-organ safety profiling.

 Organ-Specific Toxicology Biomarkers — What MSD Measures
Liver — Hepatocellular Injury (ARG1 + GST-α): Arginase-1 is liver-exclusive — elevated only when hepatocytes are damaged, eliminating muscle confound that plagues ALT/AST interpretation. GST-α is released hours before transaminases due to its small cytoplasmic size. PSTC/FDA-recognized. MSD MULTI-SPOT Liver Injury Panel measures both from 25 µL rat EDTA plasma.
Kidney — Tubular & Glomerular Injury (KIM-1, NGAL, Clusterin, Osteopontin, Cystatin C): KIM-1 is the most extensively qualified renal safety biomarker (PSTC/FDA/EMA), upregulated on proximal tubule epithelium within hours of nephrotoxic insult — preceding BUN/creatinine elevation by 24-48 hours. NGAL reflects distal tubule injury. Cystatin C provides glomerular filtration context. MSD Kidney Injury Panels 1 & 2 cover up to 7 renal analytes.
Cardiac — Myocardial Injury (cTnI, cTnT, FABP3, Myl3): Cardiac troponins I and T are the translational gold standard for myocardial injury — the same biomarkers used in clinical settings, measured via MSD with fg/mL sensitivity in preclinical species. FABP3 is an early-release cytoplasmic marker (rises before troponins). MSD Cardiac Injury Panels 2 & 3 include 3-4 cardiac markers.
Skeletal Muscle — Muscle-Specific Injury (sTnI, Myl3, FABP3): sTnI (slow-twitch skeletal troponin I) is muscle-specific — distinguishing skeletal myotoxicity from cardiac injury, which cTnI alone cannot do. Myl3 (myosin light chain 3) provides complementary muscle damage detection. MSD Muscle Injury Panels 1 & 3 separate muscle from cardiac injury in a single well.
Systemic Inflammation & Acute Phase (MCP-1, TIMP-1, TSP-1, A2M, AGP): Drug-induced organ injury triggers inflammatory responses — MCP-1 (monocyte recruitment to injured tissue), TIMP-1 (tissue remodeling, fibrosis marker), TSP-1 (TGF-β activation). Acute phase proteins (A2M, AGP) provide systemic inflammatory context alongside organ-specific markers.

Toxicology & Multi-Organ Safety Panel Configurations

Panel	Plex	Biomarkers	Species	Organ System
Liver Injury Panel 1 (MULTI-SPOT)	2	Arginase-1, GST-α	Rat	Hepatocellular Injury
Kidney Injury Panel 1	4	KIM-1/TIM-1, NGAL/Lipocalin-2, Osteopontin, Albumin	Rat	Tubular & Glomerular Injury
Kidney Injury Panel 2	7	Clusterin, Cystatin C, GST-α, KIM-1, NGAL, Osteopontin, Albumin	Rat	Comprehensive Renal Injury
Cardiac Injury Panel 2	3	cTnI, cTnT, FABP3 (H-FABP)	Rat	Myocardial Injury
Cardiac Injury Panel 3	4	cTnI, cTnT, FABP3, Myl3	Rat	Expanded Myocardial Injury
Muscle Injury Panel 1	5	cTnI, cTnT, sTnI, FABP3, Myl3	Rat	Cardiac + Skeletal Muscle
Muscle Injury Panel 3	4	cTnI, FABP3, Myl3, sTnI	Mouse	Mouse Cardiac + Skeletal Muscle
Acute Phase Protein Panel 1	2	A2M (α2-Macroglobulin), AGP (α1-Acid Glycoprotein)	Rat	Systemic Inflammation
Inflammation Panel 1	4	Lipocalin-2/NGAL, TSP-1, TIMP-1, MCP-1	Rat	Inflammatory Response

All listed panels are MSD MULTI-SPOT format for preclinical species (rat and mouse). Human liver, kidney, and cardiac singleplex assays are also available via MSD U-PLEX or R-PLEX configuration. The full 9-panel toxicology suite — liver + kidney (2 panels) + cardiac (2 panels) + muscle (2 panels) + acute phase + inflammation — can be run from ~225 µL total EDTA plasma, enabling comprehensive multi-organ safety from serial preclinical samples. Human ortholog panels are available via MSD U-PLEX or R-PLEX custom configuration. For custom multi-species toxicology studies combining rat, mouse, and NHP panels, contact us for panel compatibility and species availability. All services are for research use only.

Electrochemiluminescence for Preclinical Multi-Organ Toxicology

Advantages for Preclinical Toxicology

Serial within-animal monitoring — replace terminal sacrifice with temporal kinetics: Each MSD panel requires only 25 µL EDTA plasma. A 225 µL plasma sample from a single rat timepoint supports the full 9-panel toxicology suite. Collect pre-dose, 6h, 24h, 48h, 72h, and Day 7 samples from the same animal — generating temporal injury onset, peak, and recovery curves that terminal histopathology cannot provide. This reduces animal numbers (within-animal design vs. terminal groups) while increasing data richness.
Same platform for all organ systems — no cross-platform variability: Liver (ARG1, GST-α), kidney (KIM-1, NGAL, Clusterin), cardiac (cTnI, cTnT, FABP3), muscle (sTnI, Myl3), and inflammation (MCP-1, TIMP-1) markers all run on the same MSD instrument with identical detection chemistry and workflow. When a compound is both hepato- and nephrotoxic, the temporal relationship between liver and kidney injury onset is measured without cross-platform variability that would confound organ-to-organ comparisons.
PSTC/FDA-recognized biomarkers — regulatory context of use: KIM-1, Clusterin, Cystatin C (kidney), Arginase-1 and GST-α (liver), and cardiac troponins I/T (heart) are all recognized by the PSTC consortium as translational safety biomarkers. Using MSD for these markers provides data on a platform familiar to regulatory reviewers from published PSTC qualification studies.
Muscle vs. cardiac injury discrimination: cTnI is elevated in both myocardial and skeletal muscle injury. The MSD Muscle Injury Panels include sTnI (skeletal-specific troponin I) alongside cTnI — enabling unambiguous discrimination: elevated cTnI + normal sTnI = cardiac injury; elevated cTnI + elevated sTnI = skeletal muscle injury (or combined). This distinction is critical for compounds with potential both cardiotoxic and myotoxic effects.

Multi-Organ Toxicology Assay Specifications

TechnologyMSD (MULTI-SPOT · MULTI-ARRAY)

DetectionSULFO-TAG electrochemiluminescence

Sample Volume25 µL EDTA plasma per panel

Full Suite Volume~225 µL for all 9 panels

Sample MatrixEDTA Plasma (recommended for serial sampling)

SpeciesRat (primary), Mouse, select Human analytes

Regulatory ContextPSTC/FDA-recognized biomarkers for liver, kidney, cardiac

Throughput40 samples/plate (duplicate); 4-5 plates/day

MSD Toxicology vs Traditional Methods

Preclinical safety biomarker detection comparison

Organ Specificity MSD Organ Panels

Temporal Resolution MSD (serial)

Multi-Organ on One Platform MSD

Early Injury Detection MSD

Regulatory Familiarity Histopath

MSD provides organ-specific, serial biomarker data on one platform — complementary to histopathology. Histopathology remains the regulatory gold standard for lesion confirmation. For research use only.

Toxicology Panel Service Details

Service Package

Item	Full Service	Notes
Sample Processing	Included	Thaw, centrifuge, aliquot per panel
Standard Curves	Per-analyte 7-point calibrator	Recombinant standards in appropriate matrix
QC Samples	Multi-level, duplicate	Low, medium, high per panel
Data Normalization	Per-plate background correction	4PL logistic curve fitting, R² per analyte
Multi-Organ Report	Excel + PDF	Organ-specific sections with temporal plots, QC metrics, fold-change vs. baseline

For Research Use Only. Not for diagnostic procedures.

Serial Sampling Timeline for Multi-Organ Toxicology

within-animal serial sampling design replaces terminal sacrifice groups. Each 25 µL panel enables the full time-course from a single animal — tracking injury onset, peak, and recovery for every organ simultaneously.

Pre-dose

Day 0

Baseline
all panels

→

2–6h

Early

GST-α, KIM-1
earliest signal

→

24h

Peak

ARG1, cTnI
peak injury

→

48–72h

Recovery

Biomarker
decline

→

Day 7

Resolution

Return to
baseline?

Each timepoint: 25 µL × 9 panels = 225 µL EDTA plasma. Total study: ~1.35 mL over 6 timepoints — feasible within typical preclinical blood volume limits. All panels run on the same MSD instrument for integrated multi-organ data. For research use only.

Preclinical Toxicology Biomarker Platforms: MSD vs Clinical Chemistry vs Histopathology

Feature	MSD Multi-Organ Panels	Clinical Chemistry (ALT/AST/BUN/Cr)	Histopathology
Organ Specificity	High — organ-specific proteins (ARG1=liver, KIM-1=kidney, cTnI=heart)	Low — AST ubiquitous, BUN/Cr insensitive	Gold standard — direct lesion visualization
Temporal Resolution	Serial — within-animal time-course from 25 µL	Serial — but markers rise late, fall slowly	Terminal only — single endpoint snapshot
Detection Timing	Early — hours (GST-α, KIM-1 before ALT/BUN)	Delayed — days after injury onset	Variable — depends on lesion maturity
Multi-Organ from One Sample	Yes — 25 µL per panel, same platform	Yes — same chemistry analyzer	Yes — multi-organ tissue collection
Translational Biomarkers	Yes — same cTnI, KIM-1, NGAL as clinical settings	Yes — ALT/AST/BUN/Cr used clinically	N/A
PSTC/FDA Qualification	Yes — KIM-1, Clusterin, ARG1, GST-α, cTnI/cTnT	No — traditional, not prospectively qualified	Regulatory standard
Animal Reduction (3Rs)	Yes — within-animal design reduces group size	Yes — serial chemistry	No — requires terminal sacrifice groups

Your Multi-Organ Toxicology Data Package

Multi-organ biomarker report — organ-specific data sections (liver, kidney, cardiac, muscle, inflammation) with per-analyte concentrations and QC metrics (Excel + PDF)
Raw ECL data — per-well signal values, plate maps, standard curve parameters (4PL logistic fit, R², backfit accuracy) for each panel
Temporal injury kinetics plots — fold-change vs. pre-dose baseline across all timepoints for each organ panel; overlay plots showing multi-organ injury sequence (which organ is affected first?)
Integrated multi-organ safety summary — heatmap visualization of all organ biomarkers across timepoints, identifying the NOAEL biomarker profile and target organ toxicity ranking
Methods summary — with PSTC biomarker qualification context, organ-specific QC thresholds, and complete panel compositions for regulatory documentation

Why MSD Is Superior to Clinical Chemistry for Toxicology

Serial within-animal multi-organ profiling: 225 µL EDTA plasma supports the full 9-panel toxicology suite — liver, kidney (2 panels), cardiac (2 panels), muscle (2 panels), acute phase, and inflammation — all from the same animal at each timepoint. Generate temporal injury kinetics for every organ system without terminal sacrifice groups
Organ-specific biomarkers — no muscle confound, no delayed detection: ARG1 is liver-exclusive (unlike ALT/AST); cTnI + sTnI discriminates cardiac from skeletal muscle injury (unlike standalone troponin); KIM-1 rises within hours (unlike BUN/Cr which take days). Each marker answers a specific organ injury question without the ambiguity of traditional clinical chemistry
PSTC/FDA-recognized translational biomarkers: KIM-1, Clusterin, Cystatin C, Arginase-1, GST-α, cTnI, and cTnT are all recognized by the Predictive Safety Testing Consortium — providing regulatory-context-appropriate biomarker data using the same platform on which PSTC qualification studies were performed
Same instrument for all panels — integrated data without cross-platform variability: liver, kidney, cardiac, muscle, and inflammation markers all run on one MSD instrument with identical chemistry, workflow, and data analysis pipeline. No cross-platform normalization, no reagent incompatibility, no inter-assay variability inflation when correlating organ injury kinetics
3Rs — reduce animal numbers with within-animal serial sampling: traditional toxicology designs require terminal sacrifice groups (n=5 per timepoint × 6 timepoints = 30 animals) for histopathology. Serial MSD biomarker sampling enables within-animal designs (n=8-10 animals, sampled at all timepoints) — reducing total animals while increasing statistical power through paired longitudinal analysis

Supporting Publications

Dieterle, F. et al. (2010) Nature Biotechnology. 28(5):455-462. "Renal biomarker qualification submission: a dialog between the FDA-EMEA and PSTC." DOI: 10.1038/nbt.1625 · PMID: 20458315 — Landmark PSTC qualification of KIM-1, Clusterin, and other kidney safety biomarkers for regulatory use.
Ozer, J.S. et al. (2010) Nature Biotechnology. 28(5):486-494. "A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function." DOI: 10.1038/nbt.1627 · PMID: 20458319
Vaidya, V.S. et al. (2010) Annual Review of Pharmacology and Toxicology. 50:273-294. "Biomarkers of acute kidney injury." PMID: 20055702 — Comprehensive review of KIM-1, NGAL, and Clusterin in preclinical and clinical nephrotoxicity.
McGill, M.R. & Jaeschke, H. (2019) Biomarkers in Toxicology. Academic Press. "Biomarkers of drug-induced liver injury." — Review of Arginase-1 and GST-α as translational hepatotoxicity biomarkers qualified by PSTC.
Herman, E.H. et al. (2011) Toxicologic Pathology. 39(2):348-360. "The use of cardiac troponin I (cTnI) as a biomarker of drug-induced cardiac injury." PMID: 21343769

Multi-Organ Toxicology Panel FAQ

Which organ panels should I include for a standard preclinical toxicology study?

The minimum recommended panel set for broad-coverage preclinical safety includes: Liver Injury Panel 1 (ARG1 + GST-α — detects hepatocellular injury with organ specificity and early kinetics that ALT/AST cannot match), Kidney Injury Panel 1 or 2 (KIM-1 + NGAL ± Clusterin ± Cystatin C — tubular and glomerular injury coverage), and Cardiac Injury Panel 2 (cTnI + cTnT + FABP3 — myocardial injury with translational troponins). For compounds with known or suspected muscle toxicity, add Muscle Injury Panel 1 (cTnI + cTnT + sTnI + FABP3 + Myl3) to discriminate skeletal vs. cardiac injury. The Acute Phase Protein Panel (A2M + AGP) and Inflammation Panel 1 (MCP-1 + TIMP-1 + TSP-1) provide systemic context — useful for immunomodulatory compounds or when organ injury is accompanied by inflammatory response. All panels total ~175-225 µL EDTA plasma. For specific compound classes, we recommend discussing known target organ toxicities during project consultation to select the most informative panel combination. All services are for research use only.

How does the MSD multi-organ approach compare to traditional ALT/AST and BUN/creatinine?

Traditional clinical chemistry markers have fundamental limitations that MSD organ-specific panels address: ALT/AST lack liver specificity — AST is ubiquitous (muscle, heart, kidney, RBCs); ALT is also in muscle and kidney. Elevated AST/ALT in a preclinical study could reflect hepatotoxicity, muscle injury from restraint or injection, or both — requiring histopathology to resolve. Arginase-1 is liver-exclusive. BUN and creatinine are insensitive — they rise only after >50% nephron loss, detecting severe but not mild/moderate kidney injury. KIM-1 and NGAL rise within hours of tubular insult, before functional impairment. Traditional markers are temporally delayed — ALT/AST peak at 24-48 hours post-insult; GST-α and ARG1 peak earlier. BUN/Cr rise days after nephrotoxic insult; KIM-1 rises at 6-24 hours. MSD organ-specific panels complement, not replace, clinical chemistry — the combination of early, organ-specific biomarkers (MSD) with established functional markers (chemistry) provides the most complete preclinical safety picture.

Can human biomarker panels be used alongside rat panels for translational toxicology?

The MSD preclinical toxicology panels are primarily configured for rat and mouse. Human organ injury markers are available as individual U-PLEX or R-PLEX assays rather than pre-configured MULTI-SPOT panels. For translational toxicology studies, researchers commonly use MSD rat panels for preclinical regulatory toxicology and then bridge to human biomarkers using MSD U-PLEX custom panels — measuring the same analytes in human samples with the same ECL detection technology. This platform consistency (same detection chemistry, same instrument) reduces translational variability compared to bridging from rat MSD to human ELISA or clinical chemistry. Human kidney markers available via U-PLEX include KIM-1, NGAL, Clusterin, Cystatin C, Osteopontin, IL-18, and IP-10. Human liver markers include ARG1 and GST-α. Human cardiac markers include cTnI, cTnT, FABP3, and NT-proBNP. We can configure species-matched custom panels for translational biomarker programs — contact us to discuss your specific analytes and species requirements. All services are for research use only.

How do MSD muscle injury panels distinguish skeletal muscle from cardiac injury?

This is a critical question in preclinical toxicology because many compounds — particularly statins, fibrates, and certain kinase inhibitors — can cause both skeletal myotoxicity and cardiotoxicity. Standard cardiac troponin I (cTnI) is expressed in both cardiac and skeletal muscle (though at much lower levels in skeletal muscle), making it impossible to determine whether an elevated cTnI reflects myocardial or skeletal muscle injury from cTnI measurement alone. The MSD Muscle Injury Panels (1 and 3) include sTnI — slow-twitch skeletal troponin I — alongside cTnI, cTnT, FABP3, and Myl3. sTnI is expressed exclusively in skeletal muscle. The interpretation logic: cTnI elevated + sTnI normal = cardiac injury (myocardial-specific). cTnI elevated + sTnI elevated = skeletal muscle injury (± concurrent cardiac involvement — evaluate cTnT trend). sTnI elevated + cTnI normal = isolated skeletal muscle injury. This discrimination has previously been possible only through histopathology or isoform-specific immunohistochemistry. Myl3 (myosin light chain 3) and FABP3 provide additional muscle injury signals but are expressed in both cardiac and skeletal muscle — useful for injury magnitude quantification rather than tissue origin discrimination. For research use only.

What sample collection protocol do you recommend for multi-organ toxicology studies?

Standardized pre-analytical handling is critical for multi-organ biomarker studies because different biomarkers have different ex vivo stability profiles. Recommendations: Matrix: EDTA plasma is strongly preferred for MSD organ injury panels — KIM-1, NGAL, and GST-α can show artifactually elevated levels in serum due to platelet activation during clotting. If serum is required (e.g., for concurrent clinical chemistry), process within 30 minutes at room temperature. Processing: centrifuge at 2000×g for 10 minutes at 4°C within 1 hour of collection. Aliquot immediately — do not store samples in the primary collection tube (analyte adsorption to tube walls). Aliquot volume: 35 µL per planned panel (25 µL assay + 10 µL dead volume). Label aliquots with timepoint, animal ID, and intended panel. Storage: -80°C immediately after aliquoting. Avoid -20°C storage — some biomarkers (KIM-1, Clusterin) show degradation at -20°C over >2 weeks. Freeze-thaw: single freeze-thaw cycle only — aliquot such that each panel run uses a fresh, never-thawed aliquot. Timepoint design: pre-dose (baseline), early (2-6h for GST-α and KIM-1), peak injury (24-48h), recovery (72h-Day 7). Include a pre-dose baseline for every animal — fold-change from baseline is more informative than absolute concentration for organ injury assessment. These recommendations are for research purposes only.

Demo Assay Report

See How Your Assay Results Are Reported

Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.

Assay methods
Standard curves
QC metrics
Quantitative results

Representative formatContents vary by assay and project

RESULTS OVERVIEW

CREATIVE PROTEOMICSREPRESENTATIVE REPORT

PROTEIN & BIOMARKER ANALYSIS

Assay Report

Methods · Standard Curves · QC · Results

ASSAY SERVICESFOR RESEARCH USE ONLY

REPRESENTATIVE REPORT FORMAT Assay methods, QC metrics, and quantitative results

Demo report

Inquiry Basket

Inquiry